Status:
ENROLLING_BY_INVITATION
Biology Studies of Hematologic Cancers
Lead Sponsor:
National Cancer Institute (NCI)
Conditions:
Acute Lymphoblastic Leukemia
Myelodysplastic Syndrome (MDS)
Eligibility:
All Genders
1-120 years
Brief Summary
This study will collect tumor samples from people with cancers of the blood, bone marrow, or lymph glands for laboratory study of the biology of these conditions. Such studies contribute to a better u...
Detailed Description
Background: Laboratory-based investigations have contributed to an improved understanding of pathophysiology and to the development of new therapies for hematologic malignancies. The aim of this pro...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA
- Confirmed pathological diagnosis of any hematologic malignancy or pre-malignant blood disorder, including but not restricted to the following:
- Acute Lymphocytic Leukemia (ALL)
- Acute Myelogenous Leukemia (AML)
- Myelodysplastic Syndrome (MDS)
- Chronic Myelogenous Leukemia (CML)
- Juvenile Myelomonocytic Leukemia (JMML, J-CML)
- Non-Hodgkin's Lymphoma (NHL)
- Hodgkin's Disease
- Tumor tissue that has been previously collected and is available for study or that can be collected with minimal additional risk to the subject during sampling required for routine patient care.
- Age: \>= 1 years.
- Prior therapy: no restrictions
- Subject, parent/guardian, legally authorized representative (LAR), or durable power of attorney must be able to give informed consent and sign the informed consent document.
- EXCLUSION CRITERIA
- None
Exclusion
Key Trial Info
Start Date :
February 24 2004
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
550 Patients enrolled
Trial Details
Trial ID
NCT00923442
Start Date
February 24 2004
Last Update
January 5 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Institutes of Health Clinical Center
Bethesda, Maryland, United States, 20892